Literature DB >> 35991747

Pyomyositis presenting as myonecrosis secondary to methicillin-resistant Staphylococcus aureus bacteremia in chronic lymphocytic leukemia.

Shannon Coombs1,2, Albert Bui2, Haares S Mirzan2, Kimberly Robelin2, Hillary W Garner3, Murli Krishna4, Jennifer B Cowart2.   

Abstract

The incidence of pyomyositis in immunocompromised patients with HIV, diabetes, myelodysplastic syndromes, and acute lymphocytic leukemia is well documented. However, there are only a few reports of pyomyositis and myonecrosis in patients with chronic lymphocytic leukemia (CLL). We present a rare case of pyomyositis presenting as myonecrosis secondary to methicillin-resistant Staphylococcus aureus bacteremia in a 72-year-old patient with CLL. Pyomyositis, although rare, warrants increased provider awareness and management, especially among CLL patients who pose diagnostic and treatment challenges.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  Bacteremia; chronic lymphocytic leukemia; methicillin-resistant Staphylococcus aureus; myonecrosis; pyomyositis

Year:  2022        PMID: 35991747      PMCID: PMC9373752          DOI: 10.1080/08998280.2022.2078647

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  23 in total

Review 1.  Pyomyositis Causing Temporary Quadriparesis During Induction Therapy for Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.

Authors:  Nazanin Montazeri; Uma H Athale; Martha Fulford; Mark A Tarnopolsky
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

Review 2.  Infection of totally implantable venous access devices: A review of the literature.

Authors:  Fulvio Pinelli; Elena Cecero; Dario Degl'Innocenti; Valentina Selmi; Rosa Giua; Gianluca Villa; Cosimo Chelazzi; Stefano Romagnoli; Mauro Pittiruti
Journal:  J Vasc Access       Date:  2018-03-07       Impact factor: 2.283

3.  and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study.

Authors:  Michael Asger Andersen; Casper Tabassum Eriksen; Christian Brieghel; Jorne Lionel Biccler; Caspar da Cunha-Bang; Marie Helleberg; Carsten Utoft Niemann
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

4.  MRSA-pyomyositis in a patient with acute myelogenous leukemia after intensive chemotherapy.

Authors:  Toshihiro Fukushima; Haruka Iwao; Akio Nakazima; Miyuki Miki; Tomoyuki Sakai; Toshioki Sawaki; Masao Tanaka; Yasufumi Masaki; Yuko Hirose; Hisanori Umehara
Journal:  Anticancer Res       Date:  2009-08       Impact factor: 2.480

5.  Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.

Authors:  Michael Asger Andersen; Claus Ernst Moser; Jens Lundgren; Carsten Utoft Niemann
Journal:  Leukemia       Date:  2018-12-13       Impact factor: 11.528

6.  Bacterial pyomyositis: MRI and clinical correlation.

Authors:  Chih-Wei Yu; Jong-Kai Hsiao; Joug-Kai Hsiao; Chao-Yu Hsu; Tiffany Ting-Fang Shih
Journal:  Magn Reson Imaging       Date:  2004-11       Impact factor: 2.546

Review 7.  Chronic lymphocytic leukaemia.

Authors:  Lydia Scarfò; Andrés J M Ferreri; Paolo Ghia
Journal:  Crit Rev Oncol Hematol       Date:  2016-06-16       Impact factor: 6.312

8.  Pyomyositis: characteristics at CT and MR imaging.

Authors:  B A Gordon; S Martinez; A J Collins
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

Review 9.  Gastrointestinal Surgical Emergencies in the Neutropenic Immunocompromised Patient.

Authors:  Michael G White; Ryan B Morgan; Michael W Drazer; Oliver S Eng
Journal:  J Gastrointest Surg       Date:  2021-09-10       Impact factor: 3.452

10.  Clinical characteristics and predictors of mortality in 67 patients with primary pyomyositis: a study from North India.

Authors:  Aman Sharma; Susheel Kumar; Ajay Wanchu; Kusum Sharma; Navneet Sharma; Rajinder Singh; Pradeep Bambery; Surjit Singh; Subhash Varma
Journal:  Clin Rheumatol       Date:  2009-09-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.